NCT00033111

A Study of Cabergoline for the Treatment of Cocaine Dependence - 1

Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 140 (actual)
• Sponsor: National Institute on Drug Abuse (NIDA) · NIH
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess cabergoline for the Treatment of Cocaine Dependence

Detailed description

To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. This is a DB, placebo-controlled, parallel group design study where subjects will receive either .5mg cabergoline or placebo for 12 weeks with a 4 week follow-up.

Conditions

• Cocaine-Related Disorders
• Substance-Related Disorders

Interventions

Type	Name	Description
DRUG	Cabergoline
DRUG	Placebo	sugar pill manufactured to mimic cabergoline 05mg tablet

Timeline

• Start date: 2001-06-01
• Completion: 2004-04-01
• First posted: 2002-04-08
• Last updated: 2017-01-12

Locations

2 sites across 1 country: United States